FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Biologics

CBER Covid-19 International Collaboration

An online CBER report describes Center collaborative efforts with international partners on Covid-19.

Human Drugs

Attorney Questions Supplement Mandatory Listing

Attorney Marc Ullman argues against a proposal for mandatory dietary supplement listing with FDA as a way to improve agency enforcement.

Marketing

Guilty Plea in Compounded Drug Kickback Scheme

The Justice Department says a Florida man pleaded guilty to one count of conspiracy to violate the anti-kickback law through a compounded drug scheme.

Biologics

Bavarian Nordic Breakthrough for RSV Vaccine

FDA grants Bavarian Nordic A/S a breakthrough therapy designation for vaccine candidate MVA-BN RSV for preventing lower respiratory tract disease.

Biologics

FDA Fast Track for UCSF Gene Therapy

FDA gives Regenerative Medicine Advanced Therapy designation to a University of California San Francisco gene therapy treatment for Artemis-SCID disea...

Federal Register

Cell/Gene Therapy Panel to Hear Research Update

Federal Register notice: FDA announces a 3/10 Cellular, Tissue, and Gene Therapies Advisory Committee meeting to hear an overview of research programs...

Federal Register

Radiation Safety Standards Panel Industry Reps

Federal Register notice: FDA seeks industry organizations to help in selecting voting industry representatives to serve on CDRHs Technical Electronic ...

Intended Use Reg Neednt Curb Production: Attorneys

Two Dechert attorneys say businesses accounting for off-label uses of a drug or medical device when deciding how much to produce need not run afoul of...

Federal Register

Drug eSubmission Data Standards Updated

Federal Register notice: CDER and CBER annouces that 2/15 is the date that support begins for version 3.1.1 of the Clinical Data Interchange Standards...

Human Drugs

Rare Disease Endpoint Advancement Pilot

A Medill News Service report says part of the upcoming PDUFA reauthorization could be a Rare Disease Endpoint Advancement pilot program.